● Covered by 1 source · 1 reportHigh impact1 positive
Moderna and Merck mRNA Cancer Vaccine Reduces Melanoma Recurrence or Death by 42%
Key points
- Personalized mRNA vaccine reduced melanoma recurrence/death by 42%.
- Trial involved 1,137 stage IIB–IV melanoma patients.
- Vaccine combined with Merck's Keytruda, compared to Keytruda alone.
- Companies are engaging with regulators for approval.
Significant Trial Results Announced
Pharmaceutical companies Merck and Moderna have reported positive results from a late-stage trial for their personalized mRNA cancer vaccine. The vaccine, designed to target melanoma, reduced the risk of death or recurrence by 42% when administered in combination with standard treatment. This finding marks a notable advancement in the treatment landscape for melanoma, the most severe form of skin cancer.
Regulatory Engagement Underway
Following these trial outcomes, Merck and Moderna are now in discussions with regulatory authorities to secure approval for the vaccine. The success of this mRNA-based therapy reinforces the broader potential of mRNA technology and individualized cancer medicines to introduce new approaches in cancer treatment.
Trial Design and Details
The Phase 3 trial included 1,137 patients diagnosed with stage IIB–IV melanoma who had undergone surgical removal of their tumors. Participants were randomized, with two-thirds receiving the personalized mRNA vaccine alongside Merck's monoclonal antibody treatment Keytruda, and one-third receiving Keytruda alone. The data was presented at the European Society of Medical Oncology conference and has been accepted for publication in the New England Journal of Medicine.
Implications for Cancer Therapy
Moderna CEO Stéphane Bancel stated that the trial results validate the vision of developing cancer treatments uniquely tailored to each patient's tumor using mRNA technology. This outcome strengthens the belief that mRNA platforms could fundamentally alter how cancer is treated, moving towards more personalized and effective therapeutic strategies.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Reporting from
Moderna and Merck announced that their personalized mRNA cancer vaccine, when combined with standard treatment, reduced the risk of death or recurrence in melanoma patients by 42% in a late-stage trial. This development represents a significant advance in melanoma treatment and supports the potential of mRNA technology for individualized cancer therapies.